Serum melatonin is an alternative index of Parkinson's disease severity

Brain Research

Volumn 1547, Issue , 2014, Pages 43-48

  Lin, Ling ^a   Du, Yuequn ^a   Yuan, Sutao ^b   Shen, Jie ^a   Lin, Xiang ^c   Zheng, Zhihong ^a  

^a FUJIAN MEDICAL UNIVERSITY   (China)

^b FUJIAN PROVINCIAL HOSPITAL   (China)

^c Fujian Provincial Geriatric Hospital   (China)

Author keywords

6 Hydroxydopamin; Hoehn and Yahr scale; Parkinson's disease; Serum melatonin

Indexed keywords

APOMORPHINE; LEVODOPA; MELATONIN; OXIDOPAMINE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; ROTATION; SEX DIFFERENCE; VERY ELDERLY;

PARKINSONIA; RATTUS;

6-HYDROXYDOPAMIN; 6-HYDROXYDOPAMINE; 6-OHDA; APO; APOMORPHINE; H & Y; HOEHN AND YAHR; HOEHN AND YAHR SCALE; MELATONIN; MLT; PARKINSON'S DISEASE; PD; SEM; SERUM MELATONIN; STANDARD ERROR OF MEAN.;

AGED; AGED, 80 AND OVER; ANIMALS; APOMORPHINE; BIOLOGICAL MARKERS; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; MOTOR ACTIVITY; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84892930043     PISSN: 00068993     EISSN: 18726240     Source Type: Journal    
DOI: 10.1016/j.brainres.2013.12.021     Document Type: Article

References (27)

1. G. Atkinson, H. Jones, and B.J. Edwards et al. Effects of daytime ingestion of melatonin on short-term athletic performance Ergonomics 48 2005 1512 1522
2. A. Borah, and K.P. Mohanakumar Melatonin inhibits 6-hydroxydopamine production in the brain to protect against experimental parkinsonism in rodents J. Pineal Res. 47 2009 293 300
3. R. Bordet, D. Devos, and S. Brique et al. Study of circadian melatonin secretion patterns at different stages of Parkinson's disease Clin. Neuropharmacol. 26 2003 65 72
4. A. Boulamery, N. Simon, and J. Vidal et al. Effects of l-dopa on circadian rhythms of 6-OHDA striatal lesioned rats: a radiotelemetric study Chronobiol. Int. 27 2010 251 264
5. C. Capitelli, A. Sereniki, and M.M. Lima et al. Melatonin attenuates tyrosine hydroxylase loss and hypolocomotion in MPTP-lesioned rats Eur. J. Pharmacol. 594 2008 101 108
6. MD. Catalá, C. Cañete-Nicolás, and A. Iradi et al. Melatonin levels in Parkinson's disease: drug therapy versus electrical stimulation of the internal globus pallidus Exp. Gerontol. 32 1997 553 558
7. C.L. Comella Sleep disorders in Parkinson's disease: an overview Mov. Disord. Suppl 17 2007 S367 373
8. C.G. Goetz, W. Poewe, and O. Rascol et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations Mov. Disord. 19 2004 1020 1028
9. A. Hasegawa, K. Ohtsubo, and W. Mori Pineal gland in old age; quantitative and qualitative morphological study of 168 human autopsy cases Brain Res. 409 1987 343 349
10. S.T. Inouye, and S. Shibata Neurochemical organization of circadian rhythm in the suprachiasmatic nucleus Neurosci. Res. 20 1994 109 130
11. E.B. Klerman, H.B. Gershengorn, and J.F. Duffy et al. Comparisons of the variability of three markers of the human circadian pacemaker J. Biol. Rhythms. 17 2002 181 193
12. L. Lin, T. Meng, and T.T. Liu et al. Increased melatonin may play dual roles in the striata of a 6-hydroxydopamine model of Parkinson's disease Life Sci. 92 2013 311 316
13. J. Ma, V.E. Shaw, and J. Mitrofanis Does melatonin help save dopaminergic cells in MPTP-treated mice? Parkinsonism Relat. Disord. 15 2009 307 314
14. C.A. Medeiros, P.F. Carvalhedo de Bruin, and L.A. Lopes et al. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson's disease. A randomized, double blind, placebo-controlled study J. Neurol. 254 2007 459 464
15. M.A. Mena, M.J. Casarejos, and R.M. Solano et al. Half a century of l-DOPA Curr. Top. Med. Chem. 9 2009 880 893
16. S.R. Pandi-Perumal, A.S. Bahammam, and G.M. Brown et al. Melatonin antioxidative defense: therapeutical implications for aging and neurodegenerative processes Neurotox. Res. 23 2013 267 300
17. S. Paus, T. Schmitz-Hübsch, and U. Wüllner et al. Bright light therapy in Parkinson's disease: a pilot study Mov. Disord. 22 2007 1495 1498
18. G. Paxinos, and C. Watson The Rat Brain in Stereotaxic Coordinates 2006 Academic Press San Diego
19. E. Schernhammer, H. Chen, and B. Ritz Circulating melatonin levels: possible link between Parkinson's disease and cancer risk? Cancer Causes Control 17 2006 577 582
20. H.A. Schmid Decreased melatonin biosynthesis, calcium flux, pineal gland calcification and aging: a hypothetical framework Gerontology 39 1993 189 199
21. S. Singh, R. Ahmed, and R.K. Sagar et al. Neuroprotection of the nigrostriatal dopaminergic neurons by melatonin in hemiparkinsonium rat Indian. J. Med. Res. 124 2006 419 426
22. N.K. Singhal, G. Srivastava, and S. Agrawal et al. Melatonin as a neuroprotective agent in the rodent models of Parkinson's disease: is it all set to irrefutable clinical translation? Mol. Neurobiol. 45 2012 186 199
23. V. Tapias, J.R. Cannon, and J.T. Greenamyre Melatonin treatment potentiates neurodegeneration in a rat rotenone Parkinson's disease model J. Neurosci. Res. 88 2010 420 427
24. U. Ungerstedt, and G.W. Arbuthnott Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system Brain Res. 24 1970 485 493
25. G.L. Willis Parkinson's disease as a neuroendocrine disorder of circadian function: dopamine-melatonin imbalance and the visual system in the genesis and progression of the degenerative process Rev. Neurosci. 19 4-5 2008 245 316
26. G.L Willis, and S.M. Armstrong A therapeutic role for melatonin antagonism in experimental models of Parkinson's disease Physiol. Behav. 66 1999 785 795
27. G.L. Willis, and A.D. Robertson Recovery of experimental Parkinson's disease with the melatonin analogues ML-23 and S-20928 in a chronic, bilateral 6-OHDA model: a new mechanism involving antagonism of the melatonin receptor Pharmacol. Biochem. Behav. 79 2004 413 429